Multifaceted activity of N-acetyl-l-cysteine in chronic obstructive pulmonary disease

References

• PubChem. National center for biotechnology information. PubChem compound database; CID=12035, 2017 [cited 2017 Nov 13]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/12035
   Google Scholar
• Tirouvanziam R, Conrad CK, Bottiglieri T, et al. High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc Natl Acad Sci USA. 2006;103:4628–4633.
   PubMed Web of Science ®Google Scholar
• Prescott LF, Park J, Ballantyne A, et al. Treatment of paracetamol (acetaminophen) poisoning with N-acetylcysteine. Lancet. 1977;2:432–434.
   PubMed Web of Science ®Google Scholar
• McEvoy GK. American hospital formulary service drug information. American Society of Health-System Pharmacists (ASHP), Bethesda, US); 2013.
   Google Scholar
• Goldfrank LR, Flomenbaum NE, Lewin NA. Goldfrank’s toxicologic emergencies, ed 3. Ann Emerg Med. 2004;242:149.
   Google Scholar
• Cazzola M, Calzetta L, Facciolo F, et al. Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation. Respir Res. 2017;18:26.
   PubMed Web of Science ®Google Scholar
• Grymonpre RE, Steele JW, Schultz BR. The medication information line for the elderly. A consumer/health care professional-oriented drug information service. CPJ. 1987;120:324–326.
   PubMedGoogle Scholar
• GOLD. Global initiative for chronic obstructive lung disease. Global strategy for diagnosis, management, and prevention of COPD – 2017. [cited 2017 Jan 20] Available from: http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/
   Google Scholar
• Oka S, Kamata H, Kamata K, et al. N-acetylcysteine suppresses TNF-induced NF-kappaB activation through inhibition of IkappaB kinases. FEBS Lett. 2000;472:196–202.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Rogliani P, Facciolo F, et al. N-Acetylcysteine protects human bronchi via inhibiting neurokinin A. 1807. ERS Congress, 2017 Sept. Milan, Italy. Available from: http://www.ers-education.org/home/browse-all-content.aspx?idParent=184254
   Google Scholar
• Calzetta L, Rogliani P, Facciolo F, et al. N-Acetylcysteine protects human bronchi by modulating the release of neurokinin A in an ex vivo model of COPD exacerbation. Biomed Pharmacother. 2018;103:1–8.
   PubMed Web of Science ®Google Scholar
• Grant MJ, Booth A. A typology of reviews: an analysis of 14 review types and associated methodologies. Health Info Libr J. 2009;26:91–108.
   PubMed Web of Science ®Google Scholar
• Randell SH, Boucher RC. Effective mucus clearance is essential for respiratory health. Am J Respir Cell Mol Biol. 2006;35:20–28.
   PubMed Web of Science ®Google Scholar
• Snider GL, Lucey EC, Christensen TG, et al. Emphysema and bronchial secretory cell metaplasia induced in hamsters by human neutrophil products. Am Rev Respir Dis. 1984;129:155–160.
   PubMed Web of Science ®Google Scholar
• Robinson NP, Kyle H, Webber SE, et al. Electrolyte and other chemical concentrations in tracheal airway surface liquid and mucus. J Appl Physiol (1985). 1989;66:2129–2135.
   PubMed Web of Science ®Google Scholar
• Lundgren JD, Shelhamer JH. Pathogenesis of airway mucus hypersecretion. J Allergy Clin Immunol. 1990;85:399–417.
   PubMed Web of Science ®Google Scholar
• Sadowska AM. N-Acetylcysteine mucolysis in the management of chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2012;6:127–135.
   PubMed Web of Science ®Google Scholar
• Tse HN, Tseng CZ. Update on the pathological processes, molecular biology, and clinical utility of N-acetylcysteine in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2014;9:825–836.
   PubMed Web of Science ®Google Scholar
• Matsui H, Verghese MW, Kesimer M, et al. Reduced three-dimensional motility in dehydrated airway mucus prevents neutrophil capture and killing bacteria on airway epithelial surfaces. J Immunol. 2005;175:1090–1099.
   PubMed Web of Science ®Google Scholar
• Hurst GA, Shaw PB, LeMaistre CA. Laboratory and clinical evaluation of the mucolytic properties of acetylcysteine. Am Rev Respir Dis. 1967;96:962–970.
   PubMed Web of Science ®Google Scholar
• Aitio ML. N‐acetylcysteine–passe‐partout or much ado about nothing? Br J Clin Pharmacol. 2006;61:5–15.
   PubMed Web of Science ®Google Scholar
• Mata M, Ruiz A, Cerda M, et al. Oral N-acetylcysteine reduces bleomycin-induced lung damage and mucin Muc5ac expression in rats. Eur Respir J. 2003;22:900–905.
   PubMed Web of Science ®Google Scholar
• Martin R, Litt M, Marriott C. The effect of mucolytic agents on the rheologic and transport properties of canine tracheal mucus. Am Rev Respir Dis. 1980;121:495–500.
   PubMed Web of Science ®Google Scholar
• Rogers DF, Jeffery PK. Inhibition by oral N-acetylcysteine of cigarette smoke-induced “bronchitis” in the rat. Exp Lung Res. 1986;10:267–283.
   PubMed Web of Science ®Google Scholar
• Rogers DF, Turner NC, Marriott C, et al. Oral N-acetylcysteine or S-carboxymethylcysteine inhibit cigarette smoke-induced hypersecretion of mucus in rat larynx and trachea in situ. Eur Respir J. 1989;2:955–960.
   PubMed Web of Science ®Google Scholar
• Rogers DF, Godfrey RW, Majumdar S, et al. Oral N-acetylcysteine speeds reversal of cigarette smoke-induced mucous cell hyperplasia in the rat. Exp Lung Res. 1988;14:19–35.
   PubMed Web of Science ®Google Scholar
• Sheffner AL. The reduction in vitro in viscosity of mucoprotein solutions by a new mucolytic agent, N-acetyl-L-cysteine. Ann N Y Acad Sci. 1963;106:298–310.
   PubMed Web of Science ®Google Scholar
• Lieberman J. Measurement of sputum viscosity in a cone-plate viscometer. II. An evaluation of mucolytic agents in vitro. Am Rev Respir Dis. 1968;97:662–672.
   PubMedGoogle Scholar
• Poole PJ, Black PN. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. BMJ. 2001;322:1271–1274.
   PubMed Web of Science ®Google Scholar
• Rahman I, MacNee W. Antioxidant pharmacological therapies for COPD. Curr Opin Pharmacol. 2012;12:256–265.
   PubMed Web of Science ®Google Scholar
• Kirkham PA, Barnes PJ. Oxidative stress in COPD. Chest. 2013;144:266–273.
   PubMed Web of Science ®Google Scholar
• Fischer BM, Voynow JA, Ghio AJ. COPD: balancing oxidants and antioxidants. Int J Chron Obstruct Pulmon Dis. 2015;10:261–276.
   PubMed Web of Science ®Google Scholar
• Drost EM, Skwarski KM, Sauleda J, et al. Oxidative stress and airway inflammation in severe exacerbations of COPD. Thorax. 2005;60:293–300.
   PubMed Web of Science ®Google Scholar
• Matera MG, Calzetta L, Cazzola M. Oxidation pathway and exacerbations in COPD: the role of NAC. Expert Rev Respir Med. 2016;10:89–97.
   PubMed Web of Science ®Google Scholar
• Vina J, Saez GT, Wiggins D, et al. The effect of cysteine oxidation on isolated hepatocytes. Biochem J. 1983;212:39–44.
   PubMed Web of Science ®Google Scholar
• Rushworth GF, Megson IL. Existing and potential therapeutic uses for N-acetylcysteine: the need for conversion to intracellular glutathione for antioxidant benefits. Pharmacol Ther. 2014;141:150–159.
   PubMed Web of Science ®Google Scholar
• Moldeus P, Cotgreave IA, Berggren M. Lung protection by a thiol-containing antioxidant: N-acetylcysteine. Respiration. 1986;50(Suppl 1):31–42.
   PubMed Web of Science ®Google Scholar
• Zafarullah M, Li WQ, Sylvester J, et al. Molecular mechanisms of N-acetylcysteine actions. Cell Mol Life Sci. 2003;60:6–20.
   PubMed Web of Science ®Google Scholar
• Cotgreave IA, Berggren M, Jones TW, et al. Gastrointestinal metabolism of N-acetylcysteine in the rat, including an assay for sulfite in biological systems. Biopharm Drug Dispos. 1987;8:377–386.
   PubMed Web of Science ®Google Scholar
• Samuni Y, Goldstein S, Dean OM, et al. The chemistry and biological activities of N-acetylcysteine. Biochim Biophys Acta. 2013;1830:4117–4129.
   PubMed Web of Science ®Google Scholar
• Santus P, Corsico A, Solidoro P, et al. Oxidative stress and respiratory system: pharmacological and clinical reappraisal of N-Acetylcysteine. COPD. 2014;11:705–717.
   PubMedGoogle Scholar
• Vernooy JH, Dentener MA, van Suylen RJ, et al. Long-term intratracheal lipopolysaccharide exposure in mice results in chronic lung inflammation and persistent pathology. Am J Respir Cell Mol Biol. 2002;26:152–159.
   PubMed Web of Science ®Google Scholar
• Kharitonov S, Sjöbring U. Lipopolysaccharide challenge of humans as a model for chronic obstructive lung disease exacerbations. Contrib Microbiol. 2007;14:83–100.
   PubMedGoogle Scholar
• Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med. 2006;173:1114–1121.
   PubMed Web of Science ®Google Scholar
• Pompella A, Visvikis A, Paolicchi A, et al. The changing faces of glutathione, a cellular protagonist. Biochem Pharmacol. 2003;66:1499–1503.
   PubMed Web of Science ®Google Scholar
• Winterbourn CC, Metodiewa D. Reactivity of biologically important thiol compounds with superoxide and hydrogen peroxide. Free Radic Biol Med. 1999;27:322–328.
   PubMed Web of Science ®Google Scholar
• Bridges RB. Protective action of thiols on neutrophil function. Eur J Respir Dis Suppl. 1985;139:40–48.
   PubMedGoogle Scholar
• Voisin C, Aerts C, Wallaert B. Prevention of in vitro oxidant-mediated alveolar macrophage injury by cellular glutathione and precursors. Bull Eur Physiopathol Respir. 1987;23:309–313.
   PubMedGoogle Scholar
• Linden M, Wieslander E, Eklund A, et al. Effects of oral N-acetylcysteine on cell content and macrophage function in bronchoalveolar lavage from healthy smokers. Eur Respir J. 1988;1:645–650.
   PubMed Web of Science ®Google Scholar
• Moldeus P, Berggren M, Grafström R. N-acetylcysteine protection against the toxicity of cigarette smoke and cigarette smoke condensates in various tissues and cells in vitro. Eur J Respir Dis Suppl. 1985;139:123–129.
   PubMedGoogle Scholar
• Drost E, Lannan S, Bridgeman MM, et al. Lack of effect of N-acetylcysteine on the release of oxygen radicals from neutrophils and alveolar macrophages. Eur Respir J. 1991;4:723–729.
   PubMed Web of Science ®Google Scholar
• Schreck R, Meier B, Männel DN, et al. Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells. J Exp Med. 1992;175:1181–1194.
   PubMed Web of Science ®Google Scholar
• Desaki M, Takizawa H, Kasama T, et al. Nuclear factor-kappa b activation in silica-induced interleukin 8 production by human bronchial epithelial cells. Cytokine. 2000;12:1257–1260.
   PubMed Web of Science ®Google Scholar
• Jankowska R, Passowicz-Muszynska E, Medrala W, et al. The influence of n-acetylcysteine on chemiluminescence of granulocytes in peripheral blood of patients with chronic bronchitis. Pneumonol Alergol Pol. 1993;61:586–591, [in Polish].
   PubMedGoogle Scholar
• de Backer W, van Overveld F, Sputum VK. ECP levels in COPD patients decrease after treatment with N‐acetylcysteine (NAC). Eur Respir J. 1997;12:225s.
   Google Scholar
• Hsu BG, Lee RP, Yang FL, et al. Post-treatment with N-acetylcysteine ameliorates endotoxin shock-induced organ damage in conscious rats. Life Sci. 2006;79:2010–2016.
   PubMed Web of Science ®Google Scholar
• Bastin AJ, Davies N, Lim E, et al. Systemic inflammation and oxidative stress post-lung resection: effect of pretreatment with N-acetylcysteine. Respirology. 2016;21:180–187.
   PubMed Web of Science ®Google Scholar
• Blackwell TS, Blackwell TR, Holden EP, et al. In vivo antioxidant treatment suppresses nuclear factor-kappa B activation and neutrophilic lung inflammation. J Immunol. 1996;157:1630–1637.
   PubMed Web of Science ®Google Scholar
• Eklund A, Eriksson O, Hakansson L, et al. Oral N-acetylcysteine reduces selected humoral markers of inflammatory cell activity in BAL fluid from healthy smokers: correlation to effects on cellular variables. Eur Respir J. 1988;1:832–838.
   PubMed Web of Science ®Google Scholar
• van Overveld FJ, Vermeire PA, de Backer WA. Induced sputum of patients with chronic obstructive pulmonary disease (COPD) contains adhesion-promoting, therapy-sensitive factors. Inflamm Res. 2000;49:8–13.
   PubMed Web of Science ®Google Scholar
• Sadowska AM, Manuel YKB, de Backer WA. Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo dose-effects: a review. Pulm Pharmacol Ther. 2007;20:9–22.
   PubMed Web of Science ®Google Scholar
• Sadowska AM, van Overveld FJ, Gorecka D, et al. The interrelationship between markers of inflammation and oxidative stress in chronic obstructive pulmonary disease: modulation by inhaled steroids and antioxidant. Respir Med. 2005;99:241–249.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Luongo L, Cazzola M, et al. Contribution of sensory nerves to LPS-induced hyperresponsiveness of human isolated bronchi. Life Sci. 2015;131:44–50.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Soggiu A, Roncada P, et al. Propofol protects against opioid-induced hyperresponsiveness of airway smooth muscle in a horse model of target-controlled infusion anaesthesia. Eur J Pharmacol. 2015;765:463–471.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Page CP, et al. Protein prenylation contributes to the effects of LPS on EFS-induced responses in human isolated bronchi. Am J Respir Cell Mol Biol. 2011;45:704–710.
   PubMed Web of Science ®Google Scholar
• de Laurentiis A, Candolfi M, Pisera D, et al. Effects of lipopolysaccharide on neurokinin A content and release in the hypothalamic-pituitary axis. Regul Pept. 2003;111:91–95.
   PubMedGoogle Scholar
• Grubek-Jaworska H, Paplinska M, Hermanowicz-Salamon J, et al. IL-6 and IL-13 in induced sputum of COPD and asthma patients: correlation with respiratory tests. Respiration. 2012;84:101–107.
   PubMed Web of Science ®Google Scholar
• Bucchioni E, Kharitonov SA, Allegra L, et al. High levels of interleukin-6 in the exhaled breath condensate of patients with COPD. Respir Med. 2003;97:1299–1302.
   PubMed Web of Science ®Google Scholar
• Bhowmik A, Seemungal TA, Sapsford RJ, et al. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax. 2000;55:114–120.
   PubMed Web of Science ®Google Scholar
• Wilkinson TMA, Hurst JR, Perera WR, et al. Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD. Chest J. 2006;129:317–324.
   PubMed Web of Science ®Google Scholar
• Conrad C, Lymp J, Thompson V, et al. Long-term treatment with oral N-acetylcysteine: affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial. J Cyst Fibros. 2015;14:219–227.
   PubMed Web of Science ®Google Scholar
• Bjarnsholt T. The role of bacterial biofilms in chronic infections. APMIS Suppl. 2013;136;1–51.
   PubMedGoogle Scholar
• Lebeaux D, Ghigo J-M BC. Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics. Microbiol Mol Biol Rev. 2014;78:510–543.
   PubMed Web of Science ®Google Scholar
• Blasi F, Page C, Rossolini GM, et al. The effect of N-acetylcysteine on biofilms: implications for the treatment of respiratory tract infections. Respir Med. 2016;117:190–197.
   PubMed Web of Science ®Google Scholar
• Davies D. Understanding biofilm resistance to antibacterial agents. Nat Rev Drug Discov. 2003;2:114–122.
   PubMed Web of Science ®Google Scholar
• Hassett DJ, Borchers MT, Panos RJ. Chronic obstructive pulmonary disease (COPD): evaluation from clinical, immunological and bacterial pathogenesis perspectives. J Microbiol. 2014;52:211–226.
   PubMed Web of Science ®Google Scholar
• Eldika N, Sethi S. Role of nontypeable Haemophilus influenzae in exacerbations and progression of chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2006;12:118–124.
   PubMed Web of Science ®Google Scholar
• Martinez-Solano L, Macia MD, Fajardo A, et al. Chronic Pseudomonas aeruginosa infection in chronic obstructive pulmonary disease. Clin Infect Dis. 2008;47:1526–1533.
   PubMed Web of Science ®Google Scholar
• Perez-Giraldo C, Rodriguez-Benito A, Moran FJ, et al. Influence of N-acetylcysteine on the formation of biofilm by Staphylococcus epidermidis. J Antimicrob Chemother. 1997;39:643–646.
   PubMed Web of Science ®Google Scholar
• Lea J, Conlin AE, Sekirov I, et al. In vitro efficacy of N-acetylcysteine on bacteria associated with chronic suppurative otitis media. J Otolaryngol Head Neck Surg. 2014;43:20.
   PubMed Web of Science ®Google Scholar
• Del Prado G, Ruiz V, Naves P, et al. Biofilm formation by Streptococcus pneumoniae strains and effects of human serum albumin, ibuprofen, N-acetyl-l-cysteine, amoxicillin, erythromycin, and levofloxacin. Diagn Microbiol Infect Dis. 2010;67:311–318.
   PubMed Web of Science ®Google Scholar
• Amaral EP, Conceição EL, Costa DL, et al. N-acetyl-cysteine exhibits potent anti-mycobacterial activity in addition to its known anti-oxidative functions. BMC Microbiol. 2016;16:251.
   PubMed Web of Science ®Google Scholar
• Aslam S, Darouiche RO. Role of antibiofilm-antimicrobial agents in controlling device-related infections. Int J Artif Organs. 2011;34:752–758.
   PubMed Web of Science ®Google Scholar
• Riise GC, Qvarfordt I, Larsson S, et al. Inhibitory effect of N-acetylcysteine on adherence of Streptococcus pneumoniae and Haemophilus influenzae to human oropharyngeal epithelial cells in vitro. Respiration. 2000;67:552–558.
   PubMed Web of Science ®Google Scholar
• Zheng CH, Ahmed K, Rikitomi N, et al. The effects of S-carboxymethylcysteine and N-acetylcysteine on the adherence of Moraxella catarrhalis to human pharyngeal epithelial cells. Microbiol Immunol. 1999;43:107–113.
   PubMed Web of Science ®Google Scholar
• Morris D, Khurasany M, Nguyen T, et al. Glutathione and infection. Biochim Biophys Acta. 2013;1830:3329–3349.
   PubMed Web of Science ®Google Scholar
• Morris D, Guerra C, Khurasany M, et al. Glutathione supplementation improves macrophage functions in HIV. J Interferon Cytokine Res. 2013;33:270–279.
   PubMed Web of Science ®Google Scholar
• Landini G, Di Maggio T, Sergio F, et al. Effect of High N-Acetylcysteine concentrations on antibiotic activity against a large collection of respiratory pathogens. Antimicrob Agents Chemother. 2016;60:7513–7517.
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Aliberti S, Blasi F. Management of bronchiectasis in adults. Eur Respir J. 2015;45:1446–1462.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA. Role of viruses in exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2004;1:115–120.
   PubMedGoogle Scholar
• Sethi S, Mallia P, Johnston SL. New paradigms in the pathogenesis of chronic obstructive pulmonary disease II. Proc Am Thorac Soc. 2009;6:532–534.
   PubMedGoogle Scholar
• Mata M, Morcillo E, Gimeno C, et al. N-acetyl-L-cysteine (NAC) inhibit mucin synthesis and pro-inflammatory mediators in alveolar type II epithelial cells infected with influenza virus A and B and with respiratory syncytial virus (RSV). Biochem Pharmacol. 2011;82:548–555.
   PubMed Web of Science ®Google Scholar
• Mata M, Sarrion I, Armengot M, et al. Respiratory syncytial virus inhibits ciliagenesis in differentiated normal human bronchial epithelial cells: effectiveness of N-acetylcysteine. PLoS One. 2012;7:e48037.
   PubMed Web of Science ®Google Scholar
• Hui DS, Lee N. Adjunctive therapies and immunomodulating agents for severe influenza. Influenza Other Respir Viruses. 2013;7(Suppl 3):52–59.
   PubMed Web of Science ®Google Scholar
• Contoli M, Ito K, Padovani A, et al. Th2 cytokines impair innate immune responses to rhinovirus in respiratory epithelial cells. Allergy. 2015;70:910–920.
   PubMed Web of Science ®Google Scholar
• Biagioli MC, Kaul P, Singh I, et al. The role of oxidative stress in rhinovirus induced elaboration of IL-8 by respiratory epithelial cells. Free Radic Biol Med. 1999;26:454–462.
   PubMed Web of Science ®Google Scholar
• Spannhake EW, Reddy SPM, Jacoby DB, et al. Synergism between rhinovirus infection and oxidant pollutant exposure enhances airway epithelial cell cytokine production. Environ Health Perspect. 2002;110:665.
   PubMed Web of Science ®Google Scholar
• de Flora S, Grassi C, Carati L. Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment. Eur Respir J. 1997;10:1535–1541.
   PubMed Web of Science ®Google Scholar
• Kanai K, Koarai A, Shishikura Y, et al. Cigarette smoke augments MUC5AC production via the TLR3-EGFR pathway in airway epithelial cells. Respir Investig. 2015;53:137–148.
   PubMed Web of Science ®Google Scholar
• Mead J. Point: airway smooth muscle is useful. J Appl Physiol. 2007;102:1708–1709.
   PubMed Web of Science ®Google Scholar
• Mitzner W. Airway smooth muscle: the appendix of the lung. Am J Respir Crit Care Med. 2004;169:787–790.
   PubMed Web of Science ®Google Scholar
• Fredberg JJ. Counterpoint: airway smooth muscle is not useful. J Appl Physiol. 2007;102(1709):7587–8750.
   Google Scholar
• Seow CY, Fredberg JJ. Historical perspective on airway smooth muscle: the saga of a frustrated cell. J Appl Physiol. 2001;91:938–952.
   PubMed Web of Science ®Google Scholar
• Mitchell HW. Airway smooth muscle contraction - perspectives on past, present and future. Pulm Pharmacol Ther. 2009;22:363–369.
   PubMed Web of Science ®Google Scholar
• Zheng JP, Wen FQ, Bai CX, et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir Med. 2014;2:187–194.
   PubMed Web of Science ®Google Scholar
• Tse HN, Raiteri L, Wong KY, et al. High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study. Chest. 2013;144:106–118.
   PubMed Web of Science ®Google Scholar
• Schermer T, Chavannes N, Dekhuijzen R, et al. Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis. Respir Med. 2009;103:542–551.
   PubMed Web of Science ®Google Scholar
• Bachh AA, Shah NN, Bhargava R, et al. Effect of oral N-acetylcysteine in COPD-A randomised controlled trial. JK Pract. 2007;14:12–16.
   Google Scholar
• Decramer M, Rutten-van Molken M, Dekhuijzen PN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis randomized on NAC cost-utility study, BRONCUS): a randomised placebo-controlled trial. Lancet. 2005;365:1552–1560.
   PubMed Web of Science ®Google Scholar
• Gerrits CM, Herings RM, Leufkens HG, et al. N-acetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease. Eur Respir J. 2003;21:795–798.
   PubMed Web of Science ®Google Scholar
• Pela R, Calcagni AM, Subiaco S, et al. N-acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD. Respiration. 1999;66:495–500.
   PubMed Web of Science ®Google Scholar
• Hansen NC, Skriver A, Brorsen-Riis L, et al. Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis. Respir Med. 1994;88:531–535.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Page C, et al. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. Eur Respir Rev. 2015;24:451–461.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Rogliani P, Calzetta L, et al. Impact of mucolytic agents on COPD exacerbations: a pair-wise and network meta-analysis. COPD. 2017;14:552–563.
   PubMedGoogle Scholar
• Fowdar K, Chen H, He Z, et al. The effect of N-acetylcysteine on exacerbations of chronic obstructive pulmonary disease: a meta-analysis and systematic review. Heart Lung. 2017;46:120–128.
   PubMed Web of Science ®Google Scholar
• Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008;31:416–469.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Matera MG, Braido F, et al. Withdrawal of inhaled corticosteroids in COPD: a meta-analysis. Pulm Pharmacol Ther. 2017;45:148–158.
   PubMed Web of Science ®Google Scholar
• Jones PW, Beeh KM, Chapman KR, et al. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med. 2014;189:250–255.
   PubMed Web of Science ®Google Scholar
• NICE. National Clinical Guideline Centre. Chronic obstructive pulmonary disease in over 16s: diagnosis and management. [cited 2017 Jan 22]. Available from: https://www.nice.org.uk/guidance/CG101.
   Google Scholar
• Miravitlles M, Vogelmeier C, Roche N, et al. A review of national guidelines for management of COPD in Europe. Eur Respir J. 2016;47:625–637.
   PubMed Web of Science ®Google Scholar
• Chapman KR, Bergeron C, Bhutani M, et al. Do we know the minimal clinically important difference (MCID) for COPD exacerbations? COPD. 2013;10:243–249.
   PubMedGoogle Scholar
• Poole P, Chong J, Cates CJ. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015;7:CD001287.
   PubMed Web of Science ®Google Scholar
• de Backer J, Vos W, van Holsbeke C, et al. Effect of high-dose N-acetylcysteine on airway geometry, inflammation, and oxidative stress in COPD patients. Int J Chron Obstruct Pulmon Dis. 2013;8:569.
   PubMed Web of Science ®Google Scholar
• Johnson K, McEvoy CE, Naqvi S, et al. High-dose oral N-acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo-controlled trial. Int J Chron Obstruct Pulmon Dis. 2016;11:799–807.
   PubMed Web of Science ®Google Scholar
• Masoompour SM, Anushiravani A, Tafaroj Norouz A. Evaluation of the effect of nebulized N-acetylcysteine on respiratory secretions in mechanically ventilated patients: randomized clinical trial. Iran J Med Sci. 2015;40:309–315.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Rogliani P, et al. Impact of doxofylline in COPD: a pair-wise meta-analysis. Pulm Pharmacol Ther. 2018. DOI:10.1016/j.pupt.2018.04.010.
   Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Barnes PJ, et al. Efficacy and safety profile of xanthines in COPD: a network meta-analysis. Eur Respir Rev. 2018;27. DOI:10.1183/16000617.0010-2018.
   Web of Science ®Google Scholar